What is the latest information about jajafi and blood clots in treatment of Polycemia Vera?
Interested in more discussions like this? Go to the Blood Cancers & Disorders group.
@lwengel, as you likely already know, the USA Food and Drug Administration (FDA) approved December, 2014 a new use for ruxolitinib (Jakafi) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Ruxolitinib is the first drug approved by the FDA for this condition.
@pamdg @stevehurlburt @rspriggle may be able to add their experiences with it.
@lwengel, what kind of information are you looking for?
I had read in one article that Jakafi raises platelet levels which would increase clotting chances.
I have ET. The info I got from my hemo is that Jakafi causes weight gain and can increase hypertension. My doc said that if the HU quits working she would look at Pegasus (interferon) before Jakafi.
A few years ago, there were reports about a possible link between Jakafi. Looks like the drug's own website lists this as well as other side effects (scroll down to bottom of page): https://www.jakafi.com/
I also read that Jakafi increases chances of blood clots in PV patients.
Connect with thousands of patients and caregivers for support and answers.
Already have an account? Sign In